Bavarian Nordic A/S has significantly expanded its portfolio with the acquisition of vaccines for rabies and tick-borne encephalitis from GlaxoSmithKline Plc giving it two licensed products that can be marketed alongside its recently approved vaccine for smallpox and monkeypox infection, Jynneos. The €796 million deal includes an upfront fee of €301 million, plus performance-based milestone payments.
